Suppr超能文献

早产儿在生命的头两年中药物的使用情况。

Medication utilization in children born preterm in the first two years of life.

机构信息

Computational Health Informatics Program, Boston Children's Hospital, Boston, MA, USA.

Division of Newborn Medicine, Boston Children's Hospital, Boston, MA, USA.

出版信息

J Perinatol. 2021 Jul;41(7):1732-1738. doi: 10.1038/s41372-021-00930-0. Epub 2021 Feb 5.

Abstract

OBJECTIVE

To compare medications dispensed during the first 2 years in children born preterm and full-term.

STUDY DESIGN

Retrospective analysis of claims data from a commercial national managed care plan 2008-2019. 329,855 beneficiaries were enrolled from birth through 2 years, of which 25,408 (7.7%) were preterm (<37 weeks). Filled prescription claims and paid amount over 2 years were identified.

RESULTS

In preterm children, the number of filled prescriptions was 1.4 times and cost was 3.8 times that of full-term children. Number and cost of medications were inversely related to gestational age. Differences peak at 4-9 months and resolve by 19 months after discharge. Palivizumab, ranitidine, albuterol, lansoprazole, budesonide, and prednisolone had the greatest differences in utilization.

CONCLUSION

Prescription medication utilization among preterm children under 2 years is driven by palivizumab, anti-reflux, and respiratory medications, despite little evidence regarding efficacy for many medications and concern for harm with certain classes.

摘要

目的

比较早产儿和足月儿在出生后 2 年内所使用的药物。

研究设计

对 2008 年至 2019 年期间一个商业性全国管理式医疗计划的索赔数据进行回顾性分析。从出生到 2 岁期间有 329855 名受益人参保,其中 25408 名(7.7%)为早产儿(<37 周)。确定了 2 年内的处方用药和已支付金额。

结果

早产儿的用药处方数是足月儿的 1.4 倍,费用是足月儿的 3.8 倍。药物的数量和费用与胎龄呈负相关。差异在出生后 4-9 个月达到峰值,在出院后 19 个月后缓解。帕利珠单抗、雷尼替丁、沙丁胺醇、兰索拉唑、布地奈德和泼尼松龙的利用率差异最大。

结论

尽管许多药物的疗效证据不足,且某些药物类别存在潜在危害,但在 2 岁以下早产儿中,使用处方药物的主要原因是帕利珠单抗、抗反流和呼吸系统药物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验